Harvard Bioscience Inc HBIO
📋 Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-10-21 |
| Shares Out. | 4,510,000 |
| Website | harvardbioscience.com/ ↗ |
| Phone | 13026587581 |
| Employees | 339 |
| Revenue | $22.7M |
| Gross Profit | $12.6M |
| Net Income | -$2.9M |
| Free Cash Flow | -$1.1M |
| Total Assets | $76.3M |
| Total Liabilities | $68.9M |
| Equity | $7.4M |
About Harvard Bioscience Inc
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Harvard Bioscience Inc is a publicly traded company under the ticker symbol HBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)